WL
Weiwei Liang, MBA
Acting CFO, SVP, Business Development Transaction & Corporate Strategy
Transcenta TherapeuticsTherapeutic Areas
Transcenta Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Osemitamab (TST001) | Gastric/Gastroesophageal Junction (G/GEJ) Cancer | Phase 2/3 |
| TST002 (Blosozumab) | Osteoporosis | Phase 1 |
| TST003 | Solid Tumors | Phase 1 |